Close Menu
ArticleNewsInfo
    Facebook X (Twitter) Instagram
    ArticleNewsInfo
    • Home
    • AI
    • Tech
    • News
    • Health
    • Finance
    • Business
    • App Review
    ArticleNewsInfo
    Home»Health»Alzheimer’s Drugs Rejected for NHS Use for a Third Time
    Health

    Alzheimer’s Drugs Rejected for NHS Use for a Third Time

    Zachary WardBy Zachary WardNovember 20, 2026No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    An elderly woman with her carer sitting together in a living room.

    Two new Alzheimer’s drugs that can slow the disease will not be available on the NHS, after the National Institute for Health and Care Excellence rejected them for a third time. In final draft guidance published on 19 June 2025, NICE said donanemab, sold as Kisunla by Eli Lilly, and lecanemab, sold as Leqembi by Eisai, should not be provided on the NHS in England and Wales. Both drugs are the first treatments shown to slow early Alzheimer’s by clearing amyloid protein from the brain, delaying progression from mild to moderate disease by about four to six months. Both are licensed in Britain by the medicines regulator, the MHRA, lecanemab since August 2024 and donanemab since October 2024. NICE accepted that even a small slowing of the disease would matter to patients and carers, giving more time for independence, driving and social life. But its committee concluded the benefit was too small to justify the cost and the resources needed: fortnightly infusions for lecanemab and monthly infusions for donanemab, regular brain scans and genetic testing, and monitoring for swelling and bleeding in the brain. Both manufacturers said they would appeal.

    What the Evidence Shows

    The decision has disappointed families who hoped the drugs would be a turning point, but it also reflects a genuine dilemma. The NHS has a fixed budget, and money spent on these drugs would be money not spent on other care, including the diagnosis and support services that people with dementia need today. The drugs are available privately and in some other countries, including the United States, where they are covered by Medicare for eligible patients, which has created a two-tier picture that many find uncomfortable. Researchers say better drugs are in development, and that the first amyloid-clearing medicines have proved the disease can be slowed, which was not known a decade ago. For now, the best advice remains the everyday steps that protect the brain: staying active, controlling blood pressure, treating hearing loss and keeping socially connected. Reporting and analysis from sources such as World Health Organization track the same developments, and specialists following Alzheimer’s drugs decision say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around Alzheimer’s drugs decision is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.

    What Happens Next

    What happens next for Alzheimer’s drugs decision depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.

    There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.

    alzheimers dementia nhs
    Zachary Ward

    Related Posts

    Nearly Half of Dementia Cases Linked to Changeable Risks

    November 20, 2026

    Walking After Meals Helps Control Blood Sugar

    November 19, 2026

    FDA Adds Eye Warning to Weight-Loss Drug Labels

    November 18, 2026
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    The S&P 500’s Wild Ride to Record Highs in 2025

    November 20, 2026

    Alzheimer’s Drugs Rejected for NHS Use for a Third Time

    November 20, 2026

    Nearly Half of Dementia Cases Linked to Changeable Risks

    November 20, 2026

    Credit Scores Quietly Shape What Borrowing Costs You

    November 20, 2026

    Walking After Meals Helps Control Blood Sugar

    November 19, 2026

    Emergency Funds Give Households Room to Breathe

    November 19, 2026
    About Us

    ArticleNewsInfo is your trusted source for reliable updates, helpful insights, and trending stories. We aim to keep readers informed with accurate

    and easy-to-understand content. Our goal is to provide valuable information that helps readers stay aware and make better decisions every day. #ArticleNewsInfo

    Popular Posts

    The S&P 500’s Wild Ride to Record Highs in 2025

    November 20, 2026

    Alzheimer’s Drugs Rejected for NHS Use for a Third Time

    November 20, 2026
    Contact us

    If you have any questions or need further information, feel free to reach out to us at

    Email: tech4english@gmail. com
    Phone: +92 343 3385057

    Address: 1203 Bee Street
    Twin Lake, MI 49457

    Copyright © 2026 | All Rights Reserved | ArticleNewsInfo
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write for Us
    • Sitemap

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us